SITC 2024 Annual Meeting Schedule
View the SITC 2024 Annual Meeting schedule
Related Articles
Exploring the Complexities of Neuroendocrine Tumors and Carcinoid Heart Disease
Chair of the Department of Gastroenterology, Hepatology and Nutrition, Michelle Kang Kim, MD, PhD, joins the Cancer Advances podcast to discuss neuroendocrine tumors and carcinoid…
Current myeloproliferative neoplasm scoring systems for clinical practice
BCR::ABL1-negative myeloproliferative neoplasms (MPN) are clonal hematological malignancies resulting from the proliferation of myeloid cells harboring a J
POCUS Spotlight: Venous Excess Ultrasound Score (VExUS)
Aug 1, 2023, 02:30 AM by Eduardo R Argaiz, MD, PhD, Francisco Miralles, MD, and Abhilash Koratala, MD Cite as: Argaiz E, Miralles F, Koratala…
‘A very scary moment’: Life sciences leaders blast possibility that Trump taps RFK Jr. to run public health agencies – The Boston Globe
Kennedy, an anti-vaccine activist, reportedly said Trump had “promised” him “control” of the country’s public health agencies, including the FDA and CDC.
The Far Side of Resistance to RAS Inhibitors
Summary:. In this issue, four articles highlight the critical role of nongenetic mechanisms and cell plasticity in mediating resistance to different classes of RAS inhibitors…
The 2023 Duke-International Society for Cardiovascular Infectious Diseases Criteria for Infective Endocarditis: Updating the Modified Duke Criteria
A multinational, multidisciplinary Working Group updates the Modified Duke Criteria for infective endocarditis.
Tuning Immune‐Cold Tumor by Suppressing USP10/B7‐H4 Proteolytic Axis Reinvigorates Therapeutic Efficacy of ADCs
In immune-cold triple-negative breast cancers, elevated B7-H4 expression diminishes immune responses and impedes the efficacy of sacituzumab govitecan. The regulation of B7-H4 is a dynamic…
Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial
Camizestrant at 75 and 150 mg showed a significant benefit in progression-free survival versus fulvestrant. These results support further development of camizestrant for the treatment…